Description
The metabolism of exogenous and endogenous epoxides relies in part upon the activity of soluble epoxide hydrolase (sEH).{830} The relevance of sEH to hypertension and inflammation makes it a potentially useful clinical drug target. Specifically, the conversion of epoxyeicosatrienoic acids (EpETrEs, EETs) by sEH to the corresponding dihydroxy eicosatrienoic acids (DiHETrEs, DHETs) diminishes their vasodilator activity.{12607} Inhibitors of sEH may therefore have clinical utility for treating hypertension and systemic inflammation.{14065,14072} Cayman’s polyclonal antibody is useful for monitoring the quantity and distribution of sEH.
Synonyms: Cytosolic Epoxide Hydrolase (CEH)|EPHX2|Epoxide Hydrolase 2|sEH
Immunogen: Synthetic peptide from the internal region of human sEM
Formulation: 500 μl of peptide affinity-purified antibody
Isotype:
Applications: WB
Origin: Animal/Rabbit
Stability: 365 days
Application|Western Blot||Product Type|Antibodies|Polyclonal Antibodies||Research Area|Cardiovascular System|Cardiovascular Diseases|Hypertension||Research Area|Immunology & Inflammation
